Related Experiment Video
Updated: Mar 13, 2026
09:07
Detecting the Ligand-binding Domain Dimerization Activity of Estrogen Receptor Alpha Using the Mammalian Two-Hybrid Assay
Published on: December 19, 2018
6.9K
Multiple dynamically-coupled binding sites on human serum albumin regulate estradiol's nonlinear binding.
Mohammad Anees1, Mark K Fugate1, Shalender Bhasin1
1Research Program in Men's Health, Aging, and Metabolism, Boston Claude D. Pepper Older Americans Independence Center for Function Promoting Therapies, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
Endocrinology
|March 12, 2026
Summary
Estradiol
Area of Science:
- Biochemistry
- Molecular Biology
Background:
- Estradiol is primarily protein-bound in circulation, with human serum albumin (HSA) as the main carrier.
- Traditional views suggest low-affinity, single-site binding, but molecular details remain unclear.
Purpose of the Study:
- To characterize the molecular interactions and kinetics of estradiol-HSA binding.
- To investigate the structural and energetic basis of estradiol transport by HSA.
Main Methods:
- Utilized equilibrium dialysis, fluorescence spectroscopy, and surface plasmon resonance (SPR).
- Employed molecular docking and structure network analyses to model binding.
- Investigated estradiol-HSA interactions across various concentrations.
Main Results:
- Binding is non-linear and asymmetric, inconsistent with a fixed dissociation constant (Kd).
- SPR revealed complex association/dissociation kinetics with multiple phases.
- Identified a high-affinity site and additional moderate-affinity sites in HSA, suggesting allosteric coupling.
Conclusions:
- Estradiol-HSA binding is a dynamic, multi-equilibrium process driven by conformational changes.
- HSA actively regulates estradiol bioavailability through an allosteric binding mechanism.
- The canonical model of 1:1 stoichiometry and fixed Kd for estradiol-HSA interaction is not supported.
Related Concept Videos
01:29Drug Distribution: Plasma Protein Binding
11.0K
Drugs predominantly attach to plasma proteins, with only a small percentage remaining unbound. The unbound portion can be calculated as one minus the bound fraction. Acidic drugs form large, inactive complexes by reversibly binding to plasma albumin, which prevents them from diffusing across biological barriers. These drug-protein complexes act as reservoirs for the drugs. As the concentration of unbound drugs decreases, these complexes quickly dissociate to release the free drug, maintaining...
11.0K
02:18The Equilibrium Binding Constant and Binding Strength
15.5K
The equilibrium binding constant (Kb) quantifies the strength of a protein-ligand interaction. Kb can be calculated as follows when the reaction is at equilibrium:
15.5K
02:18The Equilibrium Binding Constant and Binding Strength
10.8K
10.8K
01:30Drug Binding to Blood Components
615
When drugs enter systemic circulation, they interact with various components of the blood, including proteins such as human serum albumin (HSA), α1-acid glycoprotein (AAG), lipoproteins, globulins, and red blood cells (RBCs).
HSA is the most abundant plasma protein and is vital in drug binding. It contains distinct drug-binding sites, with different drugs exhibiting affinity for specific sites. There are three main drug-binding domains for HSA: sites I, II, and III. These domains are...
HSA is the most abundant plasma protein and is vital in drug binding. It contains distinct drug-binding sites, with different drugs exhibiting affinity for specific sites. There are three main drug-binding domains for HSA: sites I, II, and III. These domains are...
615
01:58Cooperative Allosteric Transitions
9.3K
Cooperative allosteric transitions can occur in multimeric proteins, where each subunit of the protein has its own ligand-binding site. When a ligand binds to any of these subunits, it triggers a conformational change that affects the binding sites in the other subunits; this can change the affinity of the other sites for their respective ligands. The ability of the protein to change the shape of its binding site is attributed to the presence of a mix of flexible and stable segments in the...
9.3K
01:20Factors Affecting Protein-Drug Binding: Protein-Related Factors
637
Drug binding to proteins is a key aspect of pharmacokinetics and can influence a drug's distribution, absorption, and elimination in the body. Several factors, including the drug's physiochemical properties, protein concentration, disease states, and the number of binding sites on the protein, influence this process.
The physicochemical properties of a drug play a significant role in its ability to bind to proteins. Lipophilic drugs, which dissolve in fats, oils, and lipids, can be...
The physicochemical properties of a drug play a significant role in its ability to bind to proteins. Lipophilic drugs, which dissolve in fats, oils, and lipids, can be...
637